Actinium Pharmaceuticals raises $5.1M for drug development

12/27/2012 | PharmaLive.com

Actinium Pharmaceuticals, which specializes in alpha radioimmunotherapies for advanced cancers, has raised $5.1 million in a funding round. The company said it will use the money to advance its lead drug candidate for acute myeloid leukemia, Actimab-A, and its bone marrow conditioning agent Iomab-B, used in preparing patients for hematopoietic stem cell transplants.

View Full Article in:

PharmaLive.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT